Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of ...

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now ...

Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin-resistant tuberculosis, according to a study published in the Jan.

Now, in a major step forward, an international clinical trial has found three new safe and effective drug regimens for tuberculosis that is resistant to rifampin, the most effective of the first ...

Rifampin-resistant tuberculosis has traditionally been treated with 18-to-24-month regimens, but shorter, all-oral regimens may offer efficacious alternatives. New research findings are summarized ...